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Abstract 
Background: Nucleos(t)ide analogs (NUCs) are the standard of care for chronic hepatitis B (CHB). The present analysis 
aimed to determine the cost effectiveness of NUCs in Chinese healthcare settings.
Methods: A Markov model was used to simulate two therapeutic strategies for a hypothetical patient cohort 
diagnosed with hepatitis B e antigen-positive CHB, unwilling or unable to receive interferon therapy, and about to 
start treatment with any NUC. The first strategy included NUC monotherapy without sequencing (telbivudine [LDT], 
entecavir [ETV], tenofovir [TDF], lamivudine [LAM], adefovir dipivoxil [ADV], and combination therapies of either LDT 
and ADV or LDT and TDF, followed by best supportive care [BSC]). The second strategy included sequential therapies 
of individual NUCs: LAM → ADV, ADV → LAM, LDT → ADV, and ETV → ADV, followed by BSC. The analysis included 
two scenarios: with and without costs due to nephrotoxicity. Renal impact was quantified as costs alone, without 
consideration for quality of life decrements.
Results: When renal impact was not considered, without treatment sequencing, LDT was cost effective compared 
with other NUCs. Amongst the strategies with sequencing, LDT → ADV was cost effective. The results were similar 
when renal impact was considered. However, LDT strategy demonstrated better cost effectiveness. In probabilistic 
sensitivity analysis, in both scenarios, LDT → ADV sequence was cost effective with 51 % probability even at willing-
ness to pay of $20,000.
Conclusion: Use of LDT, as compared with other NUCs, is cost effective in CHB treatment in Chinese healthcare set-
tings. Considering the detrimental renal impact, overall costs for all treatment options were increased. However, the 
increase for LDT was comparatively small.
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Background
Approximately 240 million people worldwide are chroni-
cally infected with the hepatitis B virus (HBV) (World 
Health Organization 2015). China has the highest bur-
den, with an estimated 100 million people with chronic 
hepatitis B (CHB), translating into approximately 300,000 
annual deaths from HBV-related liver complications 
(Vellozzi and Averhoff 2016) such as end-stage liver dis-
ease and hepatocellular carcinoma (HCC) (Ng et al. 2013; 
Robotin 2011). Eradication of HBV is a national priority 
in China (Yu et  al. 2014), and various healthcare pro-
grams have been designed to address this imperative. In 
2010, the Chinese Ministry of Science and Technology 
commissioned a project to evaluate the economic bur-
den of HBV-related diseases (National Health and Family 
Planning Commission of the People’s Republic of China 
2015).
Nucleos(t)ide analogs (NUCs) represent the main-
stay of pharmacological treatment for CHB (Wong et al. 
2014). Five NUCs, namely telbivudine [LDT], entecavir 
[ETV], tenofovir [TDF], lamivudine [LAM], and ade-
fovir dipivoxil [ADV], are currently being used for the 
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treatment of CHB worldwide (Deray et al. 2015). NUCs 
primarily act by suppressing HBV replication, thereby 
minimizing the risk of liver disease progression and 
subsequent complications, including hepatic decom-
pensation and HCC, in both pre-cirrhotic and cirrhotic 
patients (Fung et al. 2011). Considering that NUC treat-
ment does not eradicate the virus, most patients require 
long-term treatment. NUCs are generally safe and well 
tolerated, but nephrotoxic effects have been reported 
with long-term treatment. Renal toxicity develops 
because of accumulation of NUC metabolites in renal 
tubular cells. Clinical evidence suggests that nephro-
toxicity is more frequent with ADV, followed by TDF 
(Deray et al. 2015). Nephrotoxicity clinically manifests as 
a decrease in glomerular filtration rate (GFR) and is more 
common in patients older than 50 years and those with 
baseline renal insufficiency, hypertension, and/or diabe-
tes mellitus. The Chinese guidelines provide recommen-
dations on the selection of effective treatments for CHB 
patients, but these are not driven by pharmacoeconomic 
evidence (Chinese Society of Hepatology and Chinese 
Society of Infectious Diseases and Chinese Medical Asso-
ciation 2011; Zhang et al. 2015). In spite of extensive use 
in clinical practice, the cost of NUCs is the primary fac-
tor that drives their real-world use as well as adherence 
among patients (Fung et  al. 2011). This is particularly 
seen in countries with limited healthcare resources, such 
as China. The Chinese healthcare setting is evolving from 
a resource-constrained scenario to a modern healthcare 
framework (Blumenthal and Hsiao 2015). In such a set-
ting, treatment strategies driven by cost-effectiveness 
evidence may help optimize case management of CHB in 
hepatitis B e antigen (HBeAg)-positive patients in China.
Multiple economic analyses have been conducted to 
compare the available NUCs in various settings (Almeida 
et al. 2012; He et al. 2012; Spackman and Veenstra 2008; 
Wu et al. 2010; Zhang et al. 2015). Nevertheless, the pre-
vious studies did not model the effects of renal impair-
ment, resistance, sequencing of treatment, or long-term 
disease progression. Hence, cost-effectiveness analyses 
are needed to determine the most cost-effective NUC(s) 
for CHB treatment. The objective of the current analysis 
was to evaluate the cost effectiveness of NUCs using two 




The first strategy included NUC treatment options with-
out sequencing: LDT, ETV, TDF, LAM, ADV, combina-
tion therapies of LDT and ADV or LDT and TDF, each 
followed by best supportive care (BSC). The second 
strategy included treatment sequencing: LAM →  ADV, 
ADV → LAM, LDT → ADV, and ETV → ADV, followed 
by BSC. It was assumed that patients with HBV resist-
ance to the first NUC would be switched to the second 
NUC, and subsequently to BSC, in the second strategy.
Model structure and description
A de novo Markov transition model was developed in MS 
Excel 2010® to estimate the cost effectiveness of NUCs in 
the treatment of CHB. This model assumed that patients 
were always in one of the finite number of health states, 
referred to as Markov states. Patients were transitioned 
among the Markov states according to a set of transition 
probabilities that depended only on the current health 
state. Patients stayed in the same health state but moved 
to the next-line treatment if they developed resistance to 
a treatment. The present health economic model con-
sisted of the following eight health states (Fig. 1):
1. Cured (generally assumed as HBeAg negative or 
hepatitis B surface antigen [HBsAg] negative and not 
corresponding to the clinical definition of cure)
2. Inactive carrier (HBsAg positive and HBeAg nega-
tive)
3. CHB
4. Compensated cirrhosis (CC)
5. Decompensated cirrhosis (DC)
6. HCC
7. Liver transplant (LT) year 1 (LT Year 1; in the year of 
transplantation)
Fig. 1 Schematic representation of the Markov model structure
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8. Liver transplant year 2 onwards (LT Year 2+; after 
first year of transplantation)
Two additional absorbing health states were consid-
ered: CHB-related death and death due to non-CHB 
causes. Transitions among the health states were deter-
mined based on disease progression and treatment effi-
cacy (Tables 1, 2). The cost-effectiveness analysis used a 
cycle length of 1 year and followed the patients for their 
entire life. The underlying assumption while construct-
ing the Markov trace for CHB patients was that HBV 
resistance would not develop in patients who move to the 
inactive carrier state (with typically low HBV DNA lev-
els) in the same cycle and/or who remain in the inactive 
carrier state. Substantial clinical evidence indicates that 
on-treatment HBV DNA levels are predictive of virologic 
resistance in CHB patients (Biazar et  al. 2015; Chang 
2009). Low rates of resistance were reported during the 
first and second years of telbivudine therapy in patients 
who achieved undetectable serum HBV DNA levels at 
treatment week 24 (Liaw 2009; Liu 2013). Furthermore, 
undetectable HBV DNA after 2 years of telbivudine treat-
ment was also reported to be associated with low telbivu-
dine resistance (Zeuzem et al. 2009).  
In the deterministic analysis, total discounted costs and 
total discounted quality-adjusted life-years (QALYs) were 
estimated. Since multiple treatment strategies were com-
pared, results were depicted on a cost-effectiveness fron-
tier. Apart from the deterministic analysis, a probabilistic 
sensitivity analysis (PSA) was also performed. For the PSA, 
β distribution was used for transition probabilities, treat-
ment effects, reactivation rates, utilities, and viral resist-
ance, whereas γ distribution was used for average eGFR 
and costs, and normal distribution for change in eGFR.
Patients discontinued the treatment if 1  year had 
elapsed after converting to HBeAg-negative status as 
per clinical guidelines (Sarin et  al. 2016). The analy-
ses involved two scenarios; the first scenario did not 
include the detrimental renal impact of the NUCs, while 
the second scenario included the nephrotoxic effects of 
the treatments. Renal impact was quantified in terms of 
costs only, and any quality of life decrements due to renal 
impact were not considered in the analysis.
Model settings
Population
The model simulated the experiences of a hypothetical 
cohort of patients who were diagnosed with HBeAg-
positive CHB, were unwilling or unable to receive inter-
feron therapy, and were about to start treatment with one 
of the NUCs. If patients developed resistance to a treat-
ment, they were assumed to stay in the same health state 
but move to the next-line treatment. The starting age of 
the cohort was 31 years, and 75 % were males. The model 
was developed with a cycle length of 1 year and followed 
patients for a lifetime.
Discounting
Costs and outcomes were discounted at 3.5 % per annum.
Length of consolidation treatment after HBeAg 
seroconversion
The model determined the impact on cost-effectiveness 
results when the treatment was continued for a minimum 
of 1 year after HBeAg seroconversion (as per the Asian-
Pacific clinical practice guidelines on the management 
of hepatitis B (Sarin et al. 2016)). Although HBsAg sero-
clearance is the ideal endpoint, it is only achievable in up 
to 12 % of patients after long-term NUC treatment (Yuen 
et al. 2016). Therefore, finite therapy (treatment of 1 year) 
based on HBeAg seroconversion, which represents the 
current standard-of-care in China, was employed in the 
model.
Perspective
The model adapted the perspectives of the Chinese 
healthcare settings.
Model inputs
Efficacy values specific to the Chinese population were 
included wherever possible for all the model inputs.
Treatment regimens
Various treatment strategies currently employed for the 
management of CHB patients in China were used (Zhang 
et al. 2015) (Table 3).
Efficacy inputs
HBsAg and HBeAg seroconversions with all treatments 
were obtained from the published literature (Table 3). The 
model included reactivation rate, i.e. patients transitioning 
from the inactive carrier state (HBeAg negative and HBsAg 
positive) to CHB status (HBeAg positive and HBsAg posi-
tive). This reactivation rate was modeled only for year 1, 
during which it is expected to be maximum. These values 
were obtained from the published literature (Table  3). It 
was assumed that the first NUC treatment would lower the 
occurrence of cirrhosis by 40  % in comparison with BSC 
(Shepherd et al. 2006). The resistance rates for the NUCs 
used in the model, along with their sources, are provided in 
Table 4 (Liaw et al. 2009; Zhang et al. 2015).
Long‑term disease progression
For BSC, long-term transition to more severe health 
states (as stated below) were obtained from a recent 
publication (Zhang et  al. 2015). As long-term data on 
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the effects of NUCs were not available, the transitions 
below were considered to be similar to those with BSC.
  • CC to DC
  • DC to dead
  • LT Year 1 to dead
  • LT Year 2+ to dead
Renal impairment inputs
The model also captured the effects of long-term use of 
NUCs on renal function. The annual changes in eGFR by 
treatment are listed in Table 5, along with their sources. 
In the analysis, an average of available data was extrapo-
lated for follow-up years. Annual changes in eGFR were 
used to estimate the eGFR of a cohort at the end of 
each cycle for a particular treatment regimen, and this 
eGFR was then used to estimate renal costs. All patients 
were assumed to start with a chronic kidney disease 
(CKD) stage 1 and an eGFR of 108.1  mL/min/1.73  m2 
(i.e. normal eGFR) (Tsai et al. 2016). When eGFR is less 
than or equal to 15 mL/min/1.73 m2, the patient would 
be considered to go on dialysis and remain on dialysis 
until renal transplantation (Tattersall et  al. 2011). In 
the base case, the waiting time for a kidney transplant 
was assumed to be 3 years, and post-transplantation the 
patient was assumed to move to CKD stage 1.
Utility inputs
Utilities were assigned for each health state (Table 6). Util-
ity inputs for the health states were derived from a previ-
ous study by Levy et al. (2008) that evaluated utilities using 
a standard gamble technique in the Chinese population.
Mortality inputs
A life table for the different age groups in China was 
derived from the World Health Organization website 
(World Health Organization 2012) and was used to cal-
culate all-cause mortality for the model.
Table 2 Other transition probabilities used in model
ADV adefovir dipivoxil, BSC best supportive care, CC compensated cirrohoiss, CHB chronic hepatitis B, DC decompensated cirrhosis, ETV entecavir, HCC hepatocellular 
carcinoma, LAM lamivudine, LDT telbivudine, LT liver transplant, NUCs nucleos(t)ide analogs, RR relative risk, TDF tenofovir
Treatment independent transitions
Transition Probability Source
Inactive carrier to cured 0.020 Shepherd et al. (2006)
Inactive carrier to CHB 0.030
Inactive carrier to CC 0.009
Cured to HCC 0.00005 Zhang et al. (2015)
Inactive carrier to HCC 0.002
CHB to CC 0.010
CHB to HCC 0.004
CHB to Dead 0.009
CC to inactive carrier 0.090 Shepherd et al. (2006)
CC to HCC 0.018 Zhang et al. (2015)
CC to dead 0.025
DC to HCC 0.091
DC to LT Year 1 0.050
HCC to Dead 0.520
Treatment specific other transitions
Transition Probability for NUCs Source
CC to DC 0.00936 (RR = 0.36) Shepherd et al. (2006)
DC to dead 0.052 (RR = 0.50)
LT Year 1 to dead 0.012 (RR = 0.1)
LT Year 2+ to dead 0.0057 (RR = 0.1)
Transition Probability for BSC Source
CC to DC 0.026 Zhang et al. (2015)
DC to dead 0.104
LT Year 1 to dead 0.120
LT Year 2+ to dead 0.057 Shepherd et al. (2006)
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Cost inputs
The various types of costs included were health state 
costs, drug costs, costs related to the management of 
renal impairment, and diagnostic costs (Table  6). The 
health state costs were primarily obtained from a study 
by Zhang et al. (2015). The drug costs were obtained from 
the IMS PADDS 2015 database. At the time of this evalu-
ation, ETV, LAM, and ADV were available as generics, 
and hence, their generic costs were included, whereas for 
LDT and TDF, the branded costs were used. All values 
Table 3 Treatment regimens used in the model
ADV adefovir dipivoxil, BSC best supportive care, ETV entecavir, LAM lamivudine, LDT telbivudine, TDF tenofovir
Treatment strategy Treatment explanation (“A → B” indicates after developing resistance to treatment A, patients move to treatment B; 
“+” indicates combination therapy)
BSC No antiviral drug treatment
LAM → BSC LAM as first-line therapy, followed by BSC as second- and third-line therapy
LDT → BSC LDT as first-line therapy, followed by BSC as second- and third-line therapy
ADV → BSC ADV as first-line therapy, followed by BSC as second- and third-line therapy
ETV → BSC ETV as first-line therapy, followed by BSC as second- and third-line therapy
TDF → BSC TDF as first-line therapy, followed by BSC as second- and third-line therapy
LDT + ADV → BSC Combination therapy of LDT and ADV as first-line therapy, followed by BSC as second- and third-line therapy
LDT + TDF → BSC Combination therapy of LDT and TDF as first-line therapy, followed by BSC as second- and third-line therapy
LAM → ADV → BSC LAM as first-line therapy, followed by ADV as second-line therapy and BSC as third-line therapy
ADV → LAM → BSC ADV as first-line therapy, followed by LAM as second-line therapy and BSC as third-line therapy
LDT → ADV → BSC LDT as first-line therapy, followed by ADV as second-line therapy and BSC as third-line therapy
ETV → ADV → BSC ETV as first-line therapy, followed by ADV as second-line therapy and BSC as third-line therapy
Table 4 Resistance profiles of antiviral therapies
ADV adefovir dipivoxil, ETV entecavir, LAM lamivudine, LDT telbivudine, TDF tenofovir
Resistance profiles
Year ADV LDT LAM ETV TDF LDT + ADV LDT + TDF
1 0 % 3 % 9 % 0 % 0 % 3 % 3 %
2 2 % 15 % 22 % 1 % 0 % 15 % 15 %
3 5 % 15 % 22 % 3 % 0 % 15 % 15 %
4 8 % 15 % 22 % 3 % 0 % 15 % 15 %
5 8 % 15 % 22 % 3 % 0 % 15 % 15 %
GLOBE trial (Liaw et al. 2009) Zhang et al. (2015) Piratvisuth et al. (2013) Conservative assumption 
of resistance of same 
as LDT
Conservative assumption of 
resistance of same as LDT
Table 5 Changes in eGFR by year for various treatment options (variation per year compared with previous year)
eGFR was measured in mL/min/1.73 m2. For the eGFR changes, for each treatment, the last available observations were carried forward till year 5
ADV adefovir dipivoxil, BSC best supportive care, eGFR estimated glomerular filtration rate, ETV entecavir, LAM lamivudine, LDT telbivudine, TDF tenofovir
Treatment Year 1 Year 2 Year 3 Year 4 Year 5 Source Year >5
TDF −6.40 0.70 0.70 0.70 0.70 Tsai et al. (2016) −0.72
LDT 9.57 5.86 10.81 10.81 10.81 Qi et al. (2015) 9.57
ETV 0.00 1.99 −3.27 −3.27 −3.27 Qi et al. (2015) −1.57
LAM −4.72 −5.40 −2.29 −2.29 −2.29 Qi et al. (2015) −3.40
ADV −6.92 −4.72 −3.74 −3.74 −3.74 Qi et al. (2015) −4.57
LDT + ADV 9.57 5.86 10.81 10.81 10.81 Assumed to be same as LDT 9.57
LDT + TDF 9.57 5.86 10.81 10.81 10.81 9.57
BSC −0.69 −0.38 −0.73 −0.73 −0.73 Qi et al. (2015) −0.65
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were presented in US dollars (USD or $), and wherever 
not available in USD, Ren Min Bi (RMB) was converted 
to USD at a rate of 6.22 RMB per USD.
Results
Deterministic results
Total discounted costs of the various treatment strate-
gies (Table  7) were interpreted using the cost-effective-
ness frontier (Fig.  2a, b). Cost-effectiveness frontier is a 
chart with the total discounted QALYs plotted along the 
x-axis and the total discounted costs along the y-axis. 
Every treatment is depicted on the chart with its total 
discounted costs and total discounted QALYs. In general, 
a treatment strategy appearing at the bottom right quad-
rant signifies that it generated large QALYs at a lower 
cost, whereas that located at the top left quadrant signi-
fies that it generated few QALYs at a considerably high 
cost. The blue line connects the cost-effective treatments. 
Treatment options that lie above this line are not consid-
ered cost effective. At present, willingness to pay (WTP) 
in China is estimated to be approximately $23,000 (3 
times the gross domestic product [GDP] of China) 
(World Bank National Accounts Data 2015; Zhang et al. 
2015). 
When renal impact was not considered, without treat-
ment sequencing, ADV and LDT were found to be more 
cost effective compared with other NUCs (Fig.  2a). The 
overall costs, QALYs and incremental cost-effectiveness 
ratios (ICERs) are presented in Table  7. Amongst the 
strategies with treatment sequencing, LDT  →  ADV 
Table 6 Cost inputs used in the China seroconversion model
ADV adefovir dipivoxil, BSC best supportive care, CKD chronic kidney disease, ETV entecavir, HBsAg hepatitis B surface antigen, LAM lamivudine, LDT telbivudine, MMF 
mycophenolate mofetil, NA not applicable, TDF tenofovir
* This cost was used to calculate disease monitoring costs. For CKD stages 1 and 2, 3, and 4 and 5, we assumed 4, 8, and 12 yearly visits, respectively
Cost parameter Annual cost ($) Source Utility Source
Heath state costs
Cured (HBsAg negative) 1315.9 Zhang et al. (2015) 0.710 Levy et al. (2008)
Inactive carrier 2237.5 0.710
Chronic hepatitis B 2237.5 0.520
Compensated cirrhosis 3468.5 0.570
Decompensated cirrhosis 6449.3 0.260
Hepatocellular carcinoma 9179.5 0.310
Liver transplant year 1 57,765.5 0.410
Liver transplant year 2+ 9626.9 0.550
Drug costs





LDT + ADV 1711.95
LDT + TDF 3768.49
BSC NA
Renal Drug Cost (tacrolimus 0.25 mg daily; MMF 2 g 
daily, and prednisolone 30 mg daily for 90 days)
2103 IMS PADDS database 2015
Procedure costs
Dialysis (for CKD 5 patients) 17,580 Dialysis cost of $17,280 (Liu 2013) (adjusted for inflation) + monitoring cost 
of $300
Transplant (for CKD 5 patients) 11,825 Transplant cost of $11,525 (Zhao et al. 2012) (adjusted for inflation) + moni-
toring cost of $300
Cost per hospital visit (assumed as unit cost of 
physician visit in China)*
25 Chinese medical news website (Woodhead 2015)
Annual examination costs
For all antiviral therapies 169.01 Zhang et al. (2015)
For BSC 175
Cost for evaluation of new patient 169
Page 8 of 12Banerjee et al. SpringerPlus  (2016) 5:1719 
was cost effective. Interestingly, ETV → ADV sequence 
may appear cost effective as it generates higher QALYs; 
however, this strategy has a high ICER ($27,205) which 
is above the acceptable WTP in comparison to the 
LDT → ADV strategy.
When renal impact was considered, LDT and 
LDT  →  ADV strategies (with or without sequencing) 
appeared to be better in terms of cost effectiveness. For 
example, the ICER of LDT to BSC was lowered from 
$4066 to $3398 (Table 7).
Probabilistic sensitivity analysis (PSA)
The uncertainty of the cost-effectiveness results for a 
range of WTP thresholds were interpreted using cost-
effectiveness acceptability (CEAC) curves. For both sce-
narios, LDT  →  ADV sequence was cost effective with 
51  % probability even at willingness to pay of $20,000. 
The next best scenario was the combination treatment 
of ETV and ADV, which was cost effective with approxi-
mately 43 % probability (Fig. 3a, b).
Discussion
CHB is one of the most common causes of chronic liver 
disease, cirrhosis and HCC worldwide (Lavanchy 2004; 
McMahon 2005). In CHB patients, glomerulonephritis 
is an important extrahepatic manifestation of the viral 
infection (Chan 2010). Particularly, with aging, sev-
eral patients present with comorbidities and various 
degrees of functional renal impairment (Deterding et al. 
2011; Ha et al. 2009; Lai et  al. 1991). Since the clinical 
management of CHB is mainly based on NUC therapy, 
there is a need for preservation of renal function in 
these patients. Such an outcome could be achieved by 
inclusion of NUCs with minimal nephrotoxicity in the 
treatment strategy. Especially in an evolving healthcare 
setting such as China, where real-world use of NUCs 
is primarily driven by costs along with clinical efficacy 
evidence (Fung et  al. 2011), treatment strategy may be 
guided by robust pharmacoeconomic evidence.
Previous studies have reported ETV as the most cost-
effective NUC and advocated its use as a first-line anti-
viral therapy/preferred treatment option in patients with 
CHB (Wu et al. 2010; Wu et al. 2012) in Chinese health-
care settings. However, treatment and disease-related 
transition rates in these studies were primarily obtained 
from the literature using cohorts from different coun-
tries, which may affect the generalizability of the results 
and may not accurately reflect the situation in China. 
Moreover, these studies did not consider the long-term 
clinical outcomes associated with use of NUCs e.g. renal 
impact or development of drug resistance.
A recent study by Zhang et  al. used a more system-
atic approach to identify the registered clinical trials 
that were based on Chinese populations and conducted 
meta-analyses to derive the parameter inputs (Zhang 
et al. 2015). The present model included inputs used by 
Zhang et  al., to ensure that parameters reflect a real-
world Chinese patient population. Long-term renal 
complications and drug resistance were modeled in this 
patient cohort, and combination and sequence therapies 
Table 7 Total discounted costs and QALYs for the treatment strategies
ADV adefovir dipivoxil, BSC best supportive care, D dominated, ED extended dominance, ETV entecavir, ICER incremental cost-effectiveness ratio, LAM lamivudine, LDT 
telbivudine, QALY quality-adjusted life-year, TDF tenofovir
Treatment strategy Cost-effectiveness analysis results without considering 
renal impact
Cost-effectiveness analysis results considering 
renal impact
Cost ($) QALYs ICER with respect to  
next best option
Cost ($) QALYs ICER with respect 
to next best option
Without sequencing
BSC 45,234 12.40 – 46,171 12.40 –
LAM 47,838 12.99 ED 48,679 12.99 ED
LDT 49,620 13.60 4066 50,257 13.60 3398
ADV 47,963 13.20 3435 52,423 13.20 D
ETV 50,640 13.71 D 51,248 13.71 D
TDF 64,413 13.27 D 65,291 13.27 D
LDT + ADV 51,829 13.66 D 52,446 13.66 D
LDT + TDF 59,267 12.78 D 60,114 12.78 D
With sequencing
LAM → ADV 48,878 13.18 D 54,976 13.18 D
ADV → LAM 48,231 13.17 D 54,560 13.17 D
LDT → ADV 50,275 13.72 5774 50,868 13.72 5385
ETV → ADV 50,819 13.74 27,205 51,422 13.74 27,741
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of NUCs were considered in the analysis. In addition to 
including similar model inputs as those in the study by 
Zhang et  al., the present study also included additional 
model parameters such as resistance profiles of NUCs 
and annual changes in eGFR with various treatments. 
Thus, the findings of the present analysis more closely 
reflect the clinical conditions of Chinese patients in real-
world settings.
Fig. 2 Cost-effectiveness frontier a without renal impact and b including renal impact. ADV adefovir dipivoxil, BSC best supportive care, CE cost-
effectiveness, ETV entecavir, LAM lamivudine, LDT telbivudine, QALY quality-adjusted life-year, TDF tenofovir
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In the study by Zhang et al., treatment with ETV gen-
erated the highest number of QALYs, resulting in 10.8 
QALYs compared with the next best result of 9.8 QALYs 
with LDT (Zhang et al. 2015). The present analysis showed 
QALY gain of 0.02 for ETV versus LDT (Table 7). In our 
model, there is a reduced difference in the rate of virologic 
resistance between LDT and ETV. Therefore, patients 
stayed longer on LDT compared with Zhang’s analy-
sis, and accordingly more patients moved to the inactive 
carrier state with LDT treatment. The benefit of ETV in 
terms of lesser resistance was apparently offset by LDT’s 
impact on moving patients to the inactive carrier state. 
Thus, both regimens appeared similar in terms of QALYs 
in the current analysis. Another factor that contributed to 
QALY gain in Zhang et al. was virologic response. As ETV 
had a higher virologic response than LDT, patients spent 
more time in the response state, thereby contributing to 
QALYs. This factor was not considered in our model.
In a real-world Chinese healthcare setting, treatment 
with NUCs leads to the development of resistance, result-
ing in a switch to the next best therapy (Chinese Society 
of Hepatology and Chinese Society of Infectious Diseases 
and Chinese Medical Association 2011). The results of 
this model indicated that LDT  →  ADV was the most 
cost-effective treatment strategy. Other real-world studies 
in Chinese populations have also reported findings that 
support the results of this pharmacoeconomic analysis. 
In a retrospective study conducted in CHB patients from 
China, the renoprotective effect of LDT was found to be 
superior to that of ADV when both were used as mono-
therapies for 1 year (Li et al. 2012). Similar findings were 
reported in other studies in the Chinese population (Gane 
et al. 2014; Wang et al. 2013). Furthermore, a recent pro-
spective cohort study provided evidence that in the Chi-
nese population, prolonged LDT therapy resulted in an 
improved eGFR, whereas ADV therapy was associated 
with a decreased eGFR and both LAM and ETV thera-
pies did not significantly influence eGFR (Qi et al. 2015). 
As renal protection is an important treatment-related 
concern in CHB patients (Deray et al. 2015), LDT offers 
clinically relevant efficacy and has a safety profile that 
may make it a possible therapeutic option for high-risk 
Fig. 3 Cost-effectiveness acceptability curve a without renal impact and b with renal impact. ADV adefovir dipivoxil, BSC best supportive care, ETV 
entecavir, LAM lamivudine, LDT telbivudine, TDF tenofovir
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patients. In addition, clinical practice guidelines recom-
mend the use of LDT in patients at an increased risk of 
renal impairment (Deray et al. 2015). The findings of the 
present analysis are in congruence with the real-world 
evidence (Gane et al. 2014; Wang et al. 2013), confirming 
the favorable clinical profile of LDT compared with other 
NUCs because of its lower renal toxicity. The findings of 
this study would enable Chinese payers to make evidence-
based justifiable decisions.
Limitations
The present model has several limitations. The meth-
odology adopted in this analysis was that of a transition 
state model that focused on HBeAg seroconversion. 
This approach is entirely based on the observations from 
HBeAg-positive patients and may not be relevant for 
HBeAg-negative patients. For a few safety inputs, par-
ticularly eGFR, the evidence was sparse, and the numeric 
values used in the model were not derived from a meta-
analytic synthesis. Furthermore, disutility due to renal 
function is expected to be different for patients in a CHB 
state versus patients in a decompensated cirrhosis state. 
Because of the lack of granular data, the current study 
could not model the differential utilities for patients in 
a CHB state versus those in decompensated cirrhosis 
state. Thus, the current analysis represents a conserva-
tive assessment or an underestimate of the cost effective-
ness of LDT given its association with improved renal 
function.
Conclusion
In this pharmacoeconomic evaluation, LDT treatment 
proved to be cost effective for CHB in Chinese health-
care settings. Considering the impact of NUCs on renal 
function, overall costs for all evaluated treatment options 
were increased. However, the increase for LDT was com-
paratively small.
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